KPRX
Financing boosts bioscience firm with $24M raise
Kiora Pharmaceuticals raised up to $24M via private placement, providing a cash runway into late 2028 while advancing clinical trials for a retinal disease therapy.
KPRX news
Latest 2 stories · newest Aug 7, 2026
KPRX
Kiora's KIO-300 suppresses seizure activity in preclinical epilepsy model
Kiora Pharmaceuticals announced preclinical data showing KIO-300 significantly reduced seizure-associated activity in a temporal lobe epilepsy model, suggesting therapeutic potential beyond its current ophthalmology focus. The findings could expand the company's ion channel modulator platform into n…
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same KPRX feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/KPRX/newsSTART FREE